LONDON, ONTARIO--(Marketwire - Jan. 26, 2012) - Stellar Pharmaceuticals Inc. (OTCQB:SLXCF)(OTCBB:SLXCF)(PINKSHEETS:SLXCF), today announced that it has received another patent from the U.S. Patent and Trademark Office (USPTO) for intellectual property central to one of the Company's lead products,

KUNMING, CHINA--(Marketwire - Jan 18, 2012) - First China Pharmaceutical Group, Inc. (OTCBB: FCPG) ("First China" or the "Company"), a rapidly growing and technologically advanced healthcare products distributor based in Yunnan, China, announced today that effective January 13, 2012, the Company has engaged EFP Rotenberg ("EFPR") as its new independent registered public accounting firm to audit the Company's current financial statements.

Dimebon Did Not Meet Primary Efficacy Endpoints: SAN FRANCISCO, CA and NEW YORK, NY--(Marketwire - Jan 17, 2012) - Medivation, Inc. (NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) today announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer's disease. Dimebon did not achieve statistically significant results for either of the two co-primary endpoints, the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog), which measures cognitive ability, or the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), which measures self care and daily function.